Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v6-FR Version v5-EN
Language French English
Date Updated 2018-10-31 2018-10-31
Drug Identification Number 02417030 02417030
Brand name BEXSERO BEXSERO
Common or Proper name Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) Multicomponent Meningococcal B Vaccine (recombinant, adsorbed)
Company Name GLAXOSMITHKLINE INC GLAXOSMITHKLINE INC
Ingredients Recombinant Neisseria meningitidis group B NHBA fusion protein Recombinant Neisseria meningitidis group B NadA protein Recombinant Neisseria meningitidis group B fHBP fusion protein Outer membrane vesicles Recombinant Neisseria meningitidis group B NHBA fusion protein Recombinant Neisseria meningitidis group B NadA protein Recombinant Neisseria meningitidis group B fHBP fusion protein Outer membrane vesicles
Strength(s) 50MCG 50MCG 50MCG 25MCG 50MCG 50MCG 50MCG 25MCG
Dosage form(s) SUSPENSION SUSPENSION
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size 1's 1's
ATC code J07AH J07AH
ATC description BACTERIAL VACCINES BACTERIAL VACCINES
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2018-10-01 2018-10-01
Estimated end date 2018-12-06 2018-12-06
Actual end date 2018-10-29 2018-10-29
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments Supply disruptions may be seen in the private market for packages of 1. Product under allocation. BEXSERO is available in packages of 10. Supply disruptions may be seen in the private market for packages of 1. Product under allocation. BEXSERO is available in packages of 10.
Health Canada comments